SCHEMBL4599672

SCHEMBL4599672

OCC(Cl)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.41
AOC3 Q16853 1/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
ALPG P10696 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GABBR2 O75899 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19877202 1.00 TRPA1 (0.41) TRPA1AOC3IDO1TDO2HDAC3
SCHEMBL6187725 1.00 TRPA1 (0.41) TRPA1AOC3IDO1TDO2HDAC3
SCHEMBL8508929 0.87 PGK1 (0.36) TRPA1ALDH1A1LMNASMN1; SMN2
SCHEMBL3421080 0.82 AOC3 (0.36) TRPA1AOC3IDO1TDO2HDAC3
SCHEMBL11017734 0.79 SLC6A3 (0.35) TRPA1AOC3IDO1TDO2HDAC3
SCHEMBL9075363 0.78 TSHR (0.48) AOC3IDO1TDO2HDAC4HDAC7
SCHEMBL7360258 0.76 AOC3 (0.38) AOC3IDO1TDO2ALDH1A1LMNA
SCHEMBL31173904 0.76 IDO1 (0.38) AOC3IDO1TDO2HDAC3HDAC4
SCHEMBL27878321 0.76 HTR2A (0.39)
SCHEMBL15011402 0.76 CES2 (0.42) HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102757325-A 2-chloro-2-aryl acetaldehyde compound and preparation method thereof UNIV ZHEJIANG 2012-10-31 CN disclosed
US-20110027264-A1 GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE SCHERING CORPORATION 2011-02-03 US disclosed
EP-1910320-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2008-04-16 EP disclosed
WO-2007011065-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110027264-A1 GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, PSEN1 TRPA1 4716/4885AOC3 3332/4885IDO1 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.